TrialCurve
Home / Trials

GLOW: reconstructed Kaplan–Meier curves

Updated 2026-09-25 · reconstructed by TrialCurve from a CC BY-licensed publication

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.

PublicationNat Med. 2023 Jul 31;29(8):2133–41. doi: 10.1038/s41591-023-02465-7
DOI10.1038/s41591-023-02465-7
RegistryNCT03653507
PhasePhase 3
ConditionsLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventionszolbetuximab, oxaliplatin, capecitabine, placebo
SponsorAstellas Pharma Global Development, Inc.
Enrolment507
Source licenceFigure published under CC BY 4.0

Progression-free survival — ITT population (all patients)

From figure panel a · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: Zolbetuximab + CAPOX 8.3 months; Placebo + CAPOX 6.8 months. Survival at 12 months: Zolbetuximab + CAPOX 36%; Placebo + CAPOX 19%. Hazard ratio Zolbetuximab + CAPOX vs Placebo + CAPOX 0.69 (95% CI 0.55–0.86).

0%20%40%60%80%100%0612182430MonthsZolbetuximab + CAPOXPlacebo + CAPOX
ArmNEventsMedian (Months)
Zolbetuximab + CAPOX2541388.3
Placebo + CAPOX2531746.8

Landmark survival (reconstructed)

TimeZolbetuximab + CAPOXPlacebo + CAPOX
6 mo70.4%60.2%
12 mo35.9%18.8%
18 mo23.4%10.3%
24 mo14.8%7.1%

Checks against the published figure

Download pseudo-IPD (CSV)

Overall survival — ITT population (all patients)

From figure panel a · validated against the values printed on the figure · curve source: vision model

Reconstructed from the published curve. Median: Zolbetuximab + CAPOX 14.4 months; Placebo + CAPOX 12.3 months. Survival at 12 months: Zolbetuximab + CAPOX 58%; Placebo + CAPOX 52%. Hazard ratio Zolbetuximab + CAPOX vs Placebo + CAPOX 0.75 (95% CI 0.60–0.94).

0%20%40%60%80%100%0612182430MonthsZolbetuximab + CAPOXPlacebo + CAPOX
ArmNEventsMedian (Months)
Zolbetuximab + CAPOX25414314.4
Placebo + CAPOX25317312.3

Landmark survival (reconstructed)

TimeZolbetuximab + CAPOXPlacebo + CAPOX
6 mo82.1%76.3%
12 mo58.4%51.5%
18 mo38.6%28.4%
24 mo29.4%17.6%

Checks against the published figure

Download pseudo-IPD (CSV)

Progression-free survival (investigator-assessed) — ITT population (all patients)

From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model

Reconstructed from the published curve. Median: Zolbetuximab + CAPOX 7.8 months; Placebo + CAPOX 6.1 months. Survival at 12 months: Zolbetuximab + CAPOX 29%; Placebo + CAPOX 17%. Hazard ratio Zolbetuximab + CAPOX vs Placebo + CAPOX 0.68 (95% CI 0.56–0.84).

0%20%40%60%80%100%0369121518212427MonthsZolbetuximab + CAPOXPlacebo + CAPOX
ArmNEventsMedian (Months)
Zolbetuximab + CAPOX2541617.8
Placebo + CAPOX2532026.1

Landmark survival (reconstructed)

TimeZolbetuximab + CAPOXPlacebo + CAPOX
6 mo64.0%52.0%
12 mo29.2%17.1%
18 mo21.2%9.5%
24 mo10.6%3.0%

Checks against the published figure

Download pseudo-IPD (CSV)

About these data

Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.

Load these data in R or Python 
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/glow-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)

# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/glow-1.csv")
for arm, g in d.groupby("arm"):
    KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()

Suggested citation: Nat Med. 2023 Jul 31;29(8):2133–41. doi: 10.1038/s41591-023-02465-7 doi:10.1038/s41591-023-02465-7. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/glow

Report a problem with these data

Related trials

Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.

Reconstruct a figure Browse all trials